Krakow, Poland – May 24, 2021 – Fidelta, a part of Selvita Group, will organize a live webinar “Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)”, followed by a Q&A session. The webinar will take place on Thursday, June 10, 2021, at 15:00 CEST; and will be held by Dr. Anamarija Markota, Team Leader In Vivo Pharmacology at Fidelta.

Systemic lupus erythematosus (SLE) is a chronic and relapsing, autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. Mouse models of lupus are not only an indispensable tool for studying lupus immunopathogenesis but also serve as a powerful system for fast screening of new SLE treatments in order to evaluate their safety and efficacy prior to clinical trials. Due to the extensive heterogenicity of clinical manifestations of SLE in humans, each mouse model displays only specific attributes of the human lupus phenotype. The upcoming webinar will give an insight into the most commonly used mouse models of SLE, highlighting their similarities and differences and discussing the advantages of using one model over the other and tailoring it for specific needs in preclinical research in the context of our current understanding of the immunopathogenesis of SLE.

Dr. Anamarija Markota is an experienced scientist and a team leader in the In vivo pharmacology department at Fidelta focusing on immunobiology and in vivo modelling of inflammatory and autoimmune disorders. After obtaining a double MSc degree in Molecular Biotechnology and Bioindustrial Techniques and a PhD degree in Immunology, Dr. Markota conducted postdoctoral research in the field of immune-oncology and immunotherapy. She has three years of experience as a study director in preclinical research, mainly in the field of IBD and SLE.

To sign up, visit: